Patients & Caregivers

Deciphera
Image
Pair of people
Our Focus on Patients

We come to work every day with a sustained commitment to helping improve the lives of patients with cancer. Each one of us at Deciphera is united in our mission to discover, develop, and deliver important new medicines to patients for the treatment of cancer.

Diseases We Target
  • Gastrointestinal Stromal Tumors (GIST)

    We believe there is a clear unmet medical need for effective and well tolerated options for patients with metastatic GIST beyond the first-line. Deciphera hopes to provide a much-needed therapeutic option for these patients for whom there are existing agents with only limited benefit or no approved treatments.

    • GIST is the most common sarcoma of the gastrointestinal tract and present most often in the stomach or small intestine.

    • According to the American Cancer Society, the total number of GIST cases each year in the United States is approximately 4,000 to about 6,000. We believe that the incidence rate in European countries to be similar to the United States.

    • Estimates for 5-year survival range from 52% to 94% depending upon the stage of the disease at diagnosis.

    • Patients diagnosed early with localized GIST generally undergo surgical resection of their tumors.

    • GIST is a disease driven initially by primary mutations in KIT kinase in approximately 80% of cases.

    • While approved kinase inhibitors control certain initiating and drug resistance-causing mutations in KIT and PDGFRA, the kinases that drive disease progression in most GIST patients, the complex heterogeneity of KIT mutations within individual tumors and individual patients is a major cause of resistance to existing therapies.

     

    GIST Clinical Studies

    icon Phase 3 Clinical Study of Ripretinib (DCC-2618) in Second-line Patients with Gastrointestinal Stromal Tumors (“INTRIGUE” Study)

    icon A Safety, Tolerability and PK Study of Ripretinib (DCC-2618) in Patients With Advanced Malignancies

     

    GIST Patients Resources

    life raft GCAF GCRF GSI SFA Sarcoma
    Sarcoma support ACS cc nord RDCRN
    GGP sarcome

     

    On this page you may select links to content published by persons not affiliated with Deciphera. The views expressed in these materials are those of the author and do not reflect the views of Deciphera. Additionally, the information contained in these materials may not be current. Deciphera disavows any obligation to correct or to update the information contained in these materials.

  • Tenosynovial Giant Cell Tumors (TGCT)

    TGCT is a rare disease caused by a translocation in the colony-stimulating factor 1 (CSF-1) gene resulting in overexpression of CSF-1 and recruitment of colony-stimulating factor 1 receptor (CSF1R)-positive inflammatory cells into the lesion. Deciphera hopes to inhibit CSF1R with vimseltinib to combat the over production of CSF-1 and the associated inflammatory changes to provide a much-needed therapeutic option for these patients.

    • TGCTs are a group of benign tumors that involve the synovium, bursae and/or tendon sheath.

    • TGCT is also known as giant cell tumor of the tendon sheath (GCT-TS) or pigmented villonodular synovitis (PVNS).

    • Although benign, these tumors can grow and cause damage to surrounding tissues and structures inducing pain, swelling, and limitation of movement of the joint.

    • A genetic mutation in certain cells within the tumor causes overproduction of CSF-1, the ligand for the CSF1R receptor, which attracts macrophages and certain other cells that become the bulk of these tumors and cause the associated inflammatory changes.

    • Surgery is the main treatment option; however, these tumors tends to recur. If untreated, or if the tumor continually recurs, damage and degeneration may occur in the affected joint and surrounding tissues, which may cause significant disability.

    • CSF1R inhibition has demonstrated clinical benefit in TGCT patients who are not amenable to surgery.

    • Despite an approved treatment for diffuse-type TGCT patients in the U.S., there remains an unmet medical need for an effective CSF1R inhibitor with a favorable safety and tolerability profile for patients with TGCT.

     

    TGCT Clinical Studies

    icon Phase 1/2 Clinical Study of DCC-3014 in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor

     

    Tenosynovial Giant Cell Tumor Clinical Study Website

     

    TGCT Patients Resources

    Sarcoma logo logo cc nord sarcome

     

    On this page you may select links to content published by persons not affiliated with Deciphera. The views expressed in these materials are those of the author and do not reflect the views of Deciphera. Additionally, the information contained in these materials may not be current. Deciphera disavows any obligation to correct or to update the information contained in these materials.